1. Cytokine-based therapy in psoriasis;Mitra;Clin Rev Allergy Immunol,2013
2. Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis;Fala;Am Health Drug Benefits,2016
3. Targeting of interleukin-17 in the treatment of psoriasis;Lønnberg;Clin Cosmet Investig Dermatol,2014
4. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis - results of two phase 3 trials;Langley;N Engl J Med,2014
5. Secukinumab longterm safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis;Kerhof;J Am Acad Dermatol,2016